study of pf-06882961 in participants with and without varying degrees of hepatic impairement

Conditions: Hepatic Impairment; Healthy Volunteers

Summary: the current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma pharmacokinetic (pk) of pf-06882961


Eligibility criteria:
inclusion criteria: * male and female participants between the ages of 18 (or the minimum country-specific age of consent if \>18) and 70 years, inclusive, at the screening visit: * participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * body mass index (bmi) of 17.5 to 38.0 kg/m2, inclusive; and a total body weight \>50 kg (110 lb), at the screening visit; with a single repeat assessment of total body weight (and hence bmi), on a separate day permitted to assess eligibility, if needed. exclusion criteria: * any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection); note: participants who have undergone cholecystectomy and/or appendectomy are eligible for this study as long as the surgery occurred more than 6 months prior to screening; * at screening, participants with a positive result for human immunodeficiency virus (hiv) antibodies, as assessed by sponsor-identified central laboratory, with a single repeat permitted to assess eligibility, if needed; * a positive covid-19 test at screening; * a diagnosis of type 2 diabetes mellitus (t2dm) that is documented by medical history; * personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men2), or participants with suspected mtc per the investigator's judgement; * other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study; * use of prior/concomitant therapies * previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product used in this study (whichever is longer); * participants with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a study involving pf-06882961; * participants with any of the following abnormalities in clinical laboratory tests at visit 1, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary: hba1c ≥6.5%; fpg ≥126 mg/dl; egfr\<60 ml/min/1.73m2; * a positive urine drug test, for illicit drugs at screening, as assessed by sponsor-identified central laboratory. however, participants in cohorts 2-4, only, who have been medically prescribed opiates/opioids or benzodiazepines and report the use of these drugs to the investigator at the screening visit will be allowed to participate; note: repeat urine drug testing is not permitted in this study; * at screening or day -1, a positive breath alcohol test, as assessed using kits provided by sponsor-identified central laboratory, with a single repeat on a separate day permitted to assess eligibility, if needed; * blood donation (excluding plasma donations) of approximately 1 pint (500 ml) or more within 60 days prior to dosing and until the follow-up contact; 13. history of sensitivity to heparin or heparin-induced thrombocytopenia, only if heparin is used to flush intravenous catheters used during serial blood collections; * unwilling or unable to comply with the criteria in the lifestyle considerations section of this protocol; * investigator site staff or pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.